Multiple Sclerosis Market Forecast. With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. These new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years. The study reviews the current and future performance of the multiple sclerosis drug class market and covers major commercial opportunities and threats ...
<shortened url>
i guess ccsvi is a"threat"
Multiple Sclerosis Market Forecast
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1579 Views
-
Last post by frodo
-
- 0 Replies
- 1637 Views
-
Last post by frodo
-
- 1 Replies
- 1838 Views
-
Last post by frodo
-
- 0 Replies
- 1787 Views
-
Last post by frodo
-
- 0 Replies
- 3637 Views
-
Last post by frodo
-
- 0 Replies
- 2233 Views
-
Last post by frodo
-
- 0 Replies
- 1882 Views
-
Last post by NHE
-
- 0 Replies
- 1263 Views
-
Last post by frodo
-
- 0 Replies
- 1432 Views
-
Last post by frodo